吉非替尼治疗晚期非小细胞肺癌的疗效与K-ras基因突变的关系分析  

Relationship Between Efficacy of Gefitinib and K-ras Gene Mutation in Patients with Advanced Non-small Cell Lung Cancer

作　　者：刘晓燕 LIU Xiaoyan(Department of Medical Oncology,Sanmenxia Central Hospital,Sanmenxia henan 472000,China)

机构地区：[1]三门峡市中心医院肿瘤内科,河南三门峡472000

出　　处：《药品评价》2020年第21期40-42,共3页Drug Evaluation

摘　　要：目的:分析吉非替尼治疗晚期非小细胞肺癌的疗效与K-ras基因突变之间的关联。方法:将本院收治的45例晚期非小细胞肺癌患者纳为研究对象,均进行吉非替尼治疗,取其石蜡包埋后的肿瘤组织样本进行K-ras基因序列分析,计算K-ras基因突变率,并进行突变相关性因素分析;以突变与否进行分组,比较吉非替尼治疗后K-ras基因突变组与野生型组的疗效及生存期。结果:K-ras基因突变率为22.22%,K-ras基因突变与患者性别、吸烟史、肿瘤分期等均无相关性(P>0.05),但与肿瘤病理分型、疗效有相关性(P<0.05);K-ras基因突变组ORR、无进展生存期及总体生存期均低于野生型组,差异存在统计学意义(P<0.05)。结论:发生K-ras基因突变的晚期非小细胞肺癌患者应用吉非替尼治疗效果有限,对该类型肿瘤的控制及生存期的改善均无积极意义。Objective:To analyze the relationship between efficacy of gefitinib and K-ras gene mutation in patients with advanced non-small cell lung cancer.Methods:Forty-five patients with advanced non-small cell lung cancer admitted to hospital were selected as study subjects and were treated with gefitinib.The tumor tissue samples after paraffin embedding were taken for K-ras gene sequence analysis,and the K-ras gene mutation rate was calculated and analysis of mutation-related factors was performed.The patients were grouped by presence or absence of mutation,and the efficacy of gefitinib and survival time were compared between the K-ras gene mutation group and the wild-type group.Results:The mutation rate of K-ras gene was 22.22%.K-ras gene mutation was not related to the gender,smoking history and tumor staging of patients(P>0.05),but was related to tumor pathological type and efficacy(P<0.05).The ORR,progression-free survival time and overall survival time of the K-ras gene mutation group were lower than those of the wild-type group(P<0.05).Conclusion:Gefitinib has limited effect on patients with advanced non-small cell lung cancer and K-ras gene mutation,and there is no positive significance in the control of this type of tumor and the improvement of survival time.

关 键 词：非小细胞肺癌 吉非替尼 K-RAS基因 

分 类 号：R979.1[医药卫生—药品]